Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis

Published:2017-06 Issue: Volume:33 Page:104-108
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Poggio F.,Ceppi M.,Lambertini M.,Bruzzi P.,Ugolini D.,Bighin C.,Levaggi A.,Giraudi S.,D'Alonzo A.,Vaglica M.,Blondeaux E.,Sertoli M.R.,Pronzato P.,Del Mastro L.

Funder

Health Ministry

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference16 articles.

1. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update;Burstein;J Clin Oncol Off J Am Soc Clin Oncol,2014

2. Adjuvant chemotherapy in luminal breast cancers;Lim;Breast Edinb Scotl,2011

3. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials;Early Breast Cancer Trialists’ Collaborative Group (EBCTCG);Lancet Lond Engl,2012

4. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor;Colleoni;Ann Oncol Off J Eur Soc Med Oncol,2005

5. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens;Osborne;J Clin Oncol Off J Am Soc Clin Oncol,1989

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of chemotherapy and endocrine treatment in breast cancer — is it still a taboo?;Oncology in Clinical Practice;2024-08-21

2. Chemotherapy combined with endocrine therapy: Old wine in a new bottle?;Clinical Breast Cancer;2024-08

3. Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial;Journal of Chemotherapy;2024-05-20

4. Efficacy and safety of concomitant chemo-endocrine therapy in neoadjuvant treatment of hormone-positive HER2-negative breast cancer: a systemic review and meta-analysis;Expert Opinion on Drug Safety;2023-04-03

5. Lycorine weakens tamoxifen resistance of breast cancer via abrogating HAGLR‐mediated epigenetic suppression on VGLL4 by DNMT1;The Kaohsiung Journal of Medical Sciences;2023-01-06